MARKET

LMDXW

LMDXW

LumiraDx Limited
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.740
+0.022
+1.28%
Closed 16:00 01/14 EST
OPEN
1.750
PREV CLOSE
1.718
HIGH
1.830
LOW
1.740
VOLUME
3.10K
TURNOVER
--
52 WEEK HIGH
2.360
52 WEEK LOW
0.4901
MARKET CAP
--
P/E (TTM)
-1.8847
1D
5D
1M
3M
1Y
5Y
BRIEF-Lumiradx Lab Analysis Confirms Its Covid-19 Antigen Test Detects The Omicron Variant
reuters.com · 2d ago
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live...
PR Newswire · 2d ago
BRIEF-LumiraDx Has Commenced Shipments In Europe For Its Covid-19 & Flu A/B Microfluidic Antigen Test
reuters.com · 5d ago
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.
PR Newswire · 5d ago
BRIEF-Lumiradx CRP Test Achieves CE Marking
reuters.com · 5d ago
BRIEF-LumiraDx Covid-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
reuters.com · 12/23/2021 11:07
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process s...
PR Newswire · 12/15/2021 13:17
How Much Of LumiraDx Limited (NASDAQ:LMDX) Do Insiders Own?
Every investor in LumiraDx Limited ( NASDAQ:LMDX ) should be aware of the most powerful shareholder groups. Large...
Simply Wall St. · 12/06/2021 11:37
More
Forecast
No Data
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LMDXW. Analyze the recent business situations of LumiraDx Limited through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
No Data
About LMDXW
LumiraDx Limited is a diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The Company has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. It has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.

Webull offers kinds of LumiraDx Ltd stock information, including NASDAQ:LMDXW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LMDXW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LMDXW stock methods without spending real money on the virtual paper trading platform.